The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has extended the licence of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor, and elexacaftor) and Kalydeco (ivacaftor) for ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug ...
Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic ...
She directed the Cystic Fibrosis Center at the former Women & Children’s Hospital of Buffalo (WCHOB) for more than 25 years, where she also served as chief of pediatric pulmonology. Borowitz is an ...
Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy Trikafta, a buyers club has resurfaced with a plan to introduce a discounted ...
Care for patients with cystic fibrosis has undergone transformative changes over the past decade and serves as an example of how an understanding of the functional consequences of a genetic disease ...
BUFFALO, N.Y. — When Dr. Drucy Borowitz and her husband moved to Buffalo in 1988, cystic fibrosis (CF) was considered a devastating childhood disease. “People died in childhood or young adulthood,” ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to ARCT-032 as a treatment for patients with cystic fibrosis, according ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results